Cel Sci Corporation (CVM)

[drkazmd65]

I think - in general the response to the data is likely to be fairly binary.

If the data show clearly that Multikine has met and exceeded its primary endpoints, Then we will see big gains in a very short period of time.

If the data show less clearly that Multikine has barely met or not met all of its primary endpoints, Then we will see some losses, especially in the short term. How bad and for how long will depend on how 'close' to meeting endpoints. So for example let's say that there only a 5-6% improvement in survivorship between the cohorts is still an improvement. This remains an improvement over SOC, and there might be some utility to Multikine anyway. In that situation CVM might be able to salvage some shareholder value despite the hit in the short-run.

If (obviously) there is no discernable improvement between Multikine+SOC and just SOC - Then the company is going to see share prices absolutely tank and will have a very hard time remaining a viable business concern.